Novel targeted therapies for NSCLC: Exploring HER2 dysregulation

2021-10-26

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC. The experts Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US This touchPODCAST is for HCPs only.

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.

The experts

Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland
Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/

Comments (3)